NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report

• <1% of cervical cancers are sarcomas. • Data on neurofibrosarcoma management is scarce. • Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance. • Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.

Guardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol Rep
Autores principales: Wells, A.E., Mallen, A.M., Bui, M.M., Reed, D.R., Apte, S.M.
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506462/
https://ncbi.nlm.nih.gov/pubmed/31080864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2019.04.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares